巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Keros Therapeutics

KROS
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Keros Therapeutics - 延遲價格・最後更新於 26/01 7:47
最高位
50.720
最低位
45.660
開市價
--
前收市價
47.590
成交量(千)
7.36
成交額(百萬)
3.30
買入
46.370
賣出
46.690
每手股數
--
市值(百萬)
1,084.88
市盈率
--
息率
--
差價
--
52週高低
75.990 - 28.500
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Keros Therapeutics
證券代碼
KROS.US
所屬板塊
Biotechnology
公司業務
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
發行量
23337862
公司總部
99 Hayden Avenue, Suite 120, Building E
公司網址
https://www.kerostx.com
公司電話
+1 617 314-6297
暫無內容

關於

Keros Therapeutics(KROS.US)所屬的行業板塊為Biotechnology。
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
詳細公司背景可參考: https://www.kerostx.com